Published in Am J Med Genet B Neuropsychiatr Genet on May 15, 2003
Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm (Vienna) (2006) 0.84
Apolipoprotein E polymorphism is associated with susceptibility to schizophrenia among Saudis. Arch Med Sci (2015) 0.76
Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet (2003) 15.31
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet (2006) 11.14
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A (2010) 4.02
Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet (2011) 4.01
Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N Engl J Med (2009) 3.88
Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet (2010) 3.69
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med (2008) 3.52
A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42
De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A (2010) 3.13
Distinct molecular phenotypes in bovine prion diseases. EMBO Rep (2004) 2.90
Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet (2011) 2.71
Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet (2012) 2.65
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) (2014) 2.37
Impaired decision making in suicide attempters. Am J Psychiatry (2005) 2.37
Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet (2010) 2.14
Abnormal cortical voice processing in autism. Nat Neurosci (2004) 2.11
Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg (2004) 2.09
Psychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders. BMC Psychiatry (2009) 2.03
French field experience with buprenorphine. Am J Addict (2004) 1.96
Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet (2011) 1.94
Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry (2008) 1.89
De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. Am J Hum Genet (2010) 1.79
Analysis of the geographical distribution of sporadic Creutzfeldt-Jakob disease in France between 1992 and 1998. Int J Epidemiol (2002) 1.70
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
ROAMER: roadmap for mental health research in Europe. Int J Methods Psychiatr Res (2014) 1.67
Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet (2007) 1.65
SHANK1 Deletions in Males with Autism Spectrum Disorder. Am J Hum Genet (2012) 1.59
Neuronal correlates of obsessions in the caudate nucleus. Biol Psychiatry (2007) 1.58
Meta-analysis of brain volume changes in obsessive-compulsive disorder. Biol Psychiatry (2008) 1.55
Fronto-striatal overactivation in euthymic bipolar patients during an emotional go/nogo task. Am J Psychiatry (2007) 1.45
Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry (2013) 1.43
A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet (2011) 1.43
Mortality in schizophrenia. Pharmacoepidemiol Drug Saf (2006) 1.41
Diogenes syndrome in a pair of siblings. Can J Psychiatry (2003) 1.40
Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol (2004) 1.40
Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci (2008) 1.39
The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences. Schizophr Bull (2007) 1.38
Conscious and subliminal conflicts in normal subjects and patients with schizophrenia: the role of the anterior cingulate. Proc Natl Acad Sci U S A (2003) 1.36
Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci (2014) 1.34
Age at onset in bipolar I affective disorder: further evidence for three subgroups. Am J Psychiatry (2003) 1.33
Screening for genomic rearrangements and methylation abnormalities of the 15q11-q13 region in autism spectrum disorders. Biol Psychiatry (2009) 1.32
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology (2010) 1.31
V180I mutation of the prion protein gene associated with atypical PrPSc glycosylation. Neurosci Lett (2006) 1.29
Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry (2008) 1.28
Executive dysfunctions as potential markers of familial vulnerability to bipolar disorder and schizophrenia. Psychiatry Res (2004) 1.27
Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 1.27
De novo SYNGAP1 mutations in nonsyndromic intellectual disability and autism. Biol Psychiatry (2011) 1.25
Neuroimaging-based markers of bipolar disorder: evidence from two meta-analyses. J Affect Disord (2011) 1.25
Prevalence of mental disorders in French prisons for men. BMC Psychiatry (2006) 1.25
Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain (2012) 1.24
Progress toward treatments for synaptic defects in autism. Nat Med (2013) 1.24
Expression and genetic variability of PCDH11Y, a gene specific to Homo sapiens and candidate for susceptibility to psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet (2006) 1.24
The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin (2003) 1.20
Admixture analysis of age at first suicide attempt. J Psychiatr Res (2009) 1.20
Assessing and interpreting personality change and continuity in patients treated for major depression. Psychol Assess (2006) 1.18
Decrease of prefrontal metabolism after subthalamic stimulation in obsessive-compulsive disorder: a positron emission tomography study. Biol Psychiatry (2010) 1.17
Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun (2013) 1.17
Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet (2003) 1.13
Autism risk factors: genes, environment, and gene-environment interactions. Dialogues Clin Neurosci (2012) 1.13
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2009) 1.12
Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry (2013) 1.12
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol (2010) 1.12
Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer (2009) 1.12
Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry (2003) 1.11
Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis. Psychol Med (2005) 1.11
Beyond genetics: childhood affective trauma in bipolar disorder. Bipolar Disord (2008) 1.11
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Affective lability and affect intensity as core dimensions of bipolar disorders during euthymic period. Psychiatry Res (2008) 1.10
Efficacy of light therapy in nonseasonal depression: a systematic review. J Affect Disord (2007) 1.10
Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1. J Neurosci (2007) 1.10
A meta-analysis of whole-brain diffusion tensor imaging studies in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09
Variant Creutzfeldt-Jakob disease in France and the United Kingdom: Evidence for the same agent strain. Ann Neurol (2009) 1.07
A mechanistic basis for amplification differences between samples and between genome regions. BMC Genomics (2012) 1.06
Faux pas detection and intentional action in Asperger Syndrome. A replication on a French sample. J Autism Dev Disord (2008) 1.06
Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry (2009) 1.05
Population-based and family-based association study of 5'UTR polymorphism of the reelin gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2005) 1.05
[Epidemiology of schizophrenic disorders]. Presse Med (2006) 1.05
Early-onset obsessive-compulsive disorder: a subgroup with a specific clinical and familial pattern? J Child Psychol Psychiatry (2005) 1.04
Association between the COMT locus and obsessive-compulsive disorder in females but not males. Am J Med Genet (2002) 1.04
Shared executive dysfunctions in unaffected relatives of patients with autism and obsessive-compulsive disorder. Eur Psychiatry (2006) 1.04
Neurological soft-signs and minor physical anomalies in schizophrenia: differential transmission within families. Schizophr Res (2003) 1.04
The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull (2015) 1.03
Prefrontal cortex dysfunction in patients with suicidal behavior. Psychol Med (2006) 1.03
Influence of prefrontal target region on the efficacy of repetitive transcranial magnetic stimulation in patients with medication-resistant depression: a [(18)F]-fluorodeoxyglucose PET and MRI study. Int J Neuropsychopharmacol (2009) 1.02
Immuno- inflammatory markers of bipolar disorder: a review of evidence. Front Biosci (Elite Ed) (2012) 1.02
A genetic family-based association study of OLIG2 in obsessive-compulsive disorder. Arch Gen Psychiatry (2007) 1.02
A first national survey of knowledge, attitudes and behaviours towards schizophrenia, bipolar disorders and autism in France. BMC Psychiatry (2012) 1.02